Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5

M. Běhounek, D. Lipcseyová, O. Vít, P. Žáček, P. Talacko, Z. Husková, S. Kikerlová, T. Tykvartová, P. Wohlfahrt, V. Melenovský, J. Beneš, J. Petrák

. 2025 ; 18 (3) : e011984. [pub] 20250117

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009677

BACKGROUND: Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis. However, no biomarker reflecting RVD is available for routine clinical use. METHODS: Proteomic analysis of myocardium from the left ventricle and right ventricle (RV) of patients with heart failure with reduced ejection fraction with (n=10) and without RVD (n=10) who underwent heart transplantation was performed. Concentrations of 2 ECM (extracellular matrix) proteins with the highest myocardial upregulation in RVD, FMOD (fibromodulin) and FBLN5 (fibulin-5), were assayed in the blood and tested in a separate cohort of patients with heart failure with reduced ejection fraction (n=232) to test for the association of the 2 proteins with RV function and long-term outcomes. RESULTS: Multivariable linear regression revealed that plasma concentrations of both FMOD and FBLN5 were significantly associated with RV function regardless of the RV function assessment method. No association of FMOD or FBLN5 with left ventricular dysfunction, cardiac index, body mass index, diabetes status, or kidney function was found. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes (P=0.005; P=0.004). Area under the curve analysis showed that the addition of FBLN5 or FMOD to RV function assessment had a significantly higher area under the curve after 4 years of follow-up (0.653 and 0.631, respectively) compared with RV function alone (0.570; P<0.05 for both). Similarly, the combination of MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score, FBLN5, and FMOD had a significantly larger area under the curve (0.669) than the combination of MAGGIC score+RVD grade (0.572; P=0.02). The Kaplan-Meier analysis demonstrated that patients with the elevation of both FMOD and FBLN5 (ie, FMOD >64 ng/mL and FMOD >27 ng/mL) had a worse prognosis than those with the elevation of either FBLN5 or FMOD (P=0.03) demonstrating the additive prognostic value of both proteins. CONCLUSIONS: Our study proposes that circulating levels of FMOD and FBLN5 may serve as new biomarkers of RVD in patients with heart failure with reduced ejection fraction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009677
003      
CZ-PrNML
005      
20250429135125.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCHEARTFAILURE.124.011984 $2 doi
035    __
$a (PubMed)39823288
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Běhounek, Matěj $u First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic $1 https://orcid.org/0000000260786653
245    10
$a Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5 / $c M. Běhounek, D. Lipcseyová, O. Vít, P. Žáček, P. Talacko, Z. Husková, S. Kikerlová, T. Tykvartová, P. Wohlfahrt, V. Melenovský, J. Beneš, J. Petrák
520    9_
$a BACKGROUND: Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis. However, no biomarker reflecting RVD is available for routine clinical use. METHODS: Proteomic analysis of myocardium from the left ventricle and right ventricle (RV) of patients with heart failure with reduced ejection fraction with (n=10) and without RVD (n=10) who underwent heart transplantation was performed. Concentrations of 2 ECM (extracellular matrix) proteins with the highest myocardial upregulation in RVD, FMOD (fibromodulin) and FBLN5 (fibulin-5), were assayed in the blood and tested in a separate cohort of patients with heart failure with reduced ejection fraction (n=232) to test for the association of the 2 proteins with RV function and long-term outcomes. RESULTS: Multivariable linear regression revealed that plasma concentrations of both FMOD and FBLN5 were significantly associated with RV function regardless of the RV function assessment method. No association of FMOD or FBLN5 with left ventricular dysfunction, cardiac index, body mass index, diabetes status, or kidney function was found. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes (P=0.005; P=0.004). Area under the curve analysis showed that the addition of FBLN5 or FMOD to RV function assessment had a significantly higher area under the curve after 4 years of follow-up (0.653 and 0.631, respectively) compared with RV function alone (0.570; P<0.05 for both). Similarly, the combination of MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score, FBLN5, and FMOD had a significantly larger area under the curve (0.669) than the combination of MAGGIC score+RVD grade (0.572; P=0.02). The Kaplan-Meier analysis demonstrated that patients with the elevation of both FMOD and FBLN5 (ie, FMOD >64 ng/mL and FMOD >27 ng/mL) had a worse prognosis than those with the elevation of either FBLN5 or FMOD (P=0.03) demonstrating the additive prognostic value of both proteins. CONCLUSIONS: Our study proposes that circulating levels of FMOD and FBLN5 may serve as new biomarkers of RVD in patients with heart failure with reduced ejection fraction.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a srdeční selhání $x patofyziologie $x metabolismus $x krev $7 D006333
650    12
$a biologické markery $x krev $7 D015415
650    12
$a proteomika $x metody $7 D040901
650    12
$a tepový objem $x fyziologie $7 D013318
650    _2
$a senioři $7 D000368
650    12
$a fibromodulin $7 D000071235
650    _2
$a funkce pravé komory srdeční $x fyziologie $7 D016278
650    _2
$a prognóza $7 D011379
650    _2
$a extracelulární matrix - proteiny $x krev $x metabolismus $7 D016326
650    _2
$a funkce levé komory srdeční $x fyziologie $7 D016277
650    _2
$a transplantace srdce $7 D016027
650    _2
$a srdeční komory $x patofyziologie $x metabolismus $7 D006352
650    _2
$a proteiny vázající vápník $x krev $x metabolismus $7 D002135
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lipcseyová, Denisa $u First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic $1 https://orcid.org/0000000161208794
700    1_
$a Vít, Ondřej $u First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic
700    1_
$a Žáček, Petr $u Proteomic Core Facility, Faculty of Science (P.Z., P.T.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic
700    1_
$a Talacko, Pavel $u Proteomic Core Facility, Faculty of Science (P.Z., P.T.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic
700    1_
$a Husková, Zuzana $u Proteomic Core Facility, Faculty of Science (P.Z., P.T.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic
700    1_
$a Kikerlová, Soňa $u Center of Experimental Medicine (Z.H., S.K.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Tykvartová, Tereza $u Department of Cardiology (T.T., P.W., V.M., J.B.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Wohlfahrt, Peter $u Department of Cardiology (T.T., P.W., V.M., J.B.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology (T.T., P.W., V.M., J.B.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Beneš, Jan $u Department of Cardiology (T.T., P.W., V.M., J.B.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City (J.B.) $1 https://orcid.org/0000000283045612
700    1_
$a Petrák, Jiří $u First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic $1 https://orcid.org/0000000286954803
773    0_
$w MED00159985 $t Circulation. Heart failure $x 1941-3297 $g Roč. 18, č. 3 (2025), s. e011984
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39823288 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135121 $b ABA008
999    __
$a ok $b bmc $g 2311196 $s 1246758
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 18 $c 3 $d e011984 $e 20250117 $i 1941-3297 $m Circulation. Heart failure $n Circ Heart Fail $x MED00159985
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace